LSX

Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer

Retrieved on: 
Monday, April 22, 2024
FDA, PAM, ABC, Safety, Food, Prognosis, AKT, Patient, S6K, CMC, Acquisition, CSO, LSX, Breast cancer, ESR1, Pharmaceutical industry

Following a Type B meeting held on March 13, 2024, the U.S. Food and Drug Administration (FDA) provided Evexta Bio with valuable input on various aspects of rupitasertib development, including CMC, preclinical and clinical topics, enabling the company to proceed with the Phase 2 study in advanced breast cancer.

Key Points: 
  • Following a Type B meeting held on March 13, 2024, the U.S. Food and Drug Administration (FDA) provided Evexta Bio with valuable input on various aspects of rupitasertib development, including CMC, preclinical and clinical topics, enabling the company to proceed with the Phase 2 study in advanced breast cancer.
  • Recent preclinical studies in ESR1mt breast cancer models have shown compelling synergistic effects of rupitasertib administered in combination with elacestrant.
  • These data support the preliminary clinical efficacy observed in the Phase 1 study and warrant the development of rupitasertib in ESR1mt ER+ HER2- advanced breast cancer patients.
  • In addition, S6K has been shown to be closely associated with the emergence of cancer resistance, particularly in breast cancer, through ER modulation.

Pattern to Present in London, UK at the LSX World Congress

Retrieved on: 
Wednesday, April 17, 2024
Congress, Investment, AI, Research, Medtech, Business, Pattern, LSX, Cancer, PDE, Management

REDMOND, Wash., April 16, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will be presenting at the LSX World Congress which will take place in London, UK on April 29-30, 2024, at the Business Design Center.

Key Points: 
  • REDMOND, Wash., April 16, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will be presenting at the LSX World Congress which will take place in London, UK on April 29-30, 2024, at the Business Design Center.
  • LSX World Congress is the leading partnering, strategy, and investment event in Europe, with a strong focus on one-to-one partnering.
  • “Pattern is a pioneer in finding novel patterns in complex data that cannot be discovered using other techniques or tools,” commented Mr. Anderson.
  • Pattern is optimally positioned to leverage the expertise of our Pattern Discovery Engine™ (PDE) into the next worlds of trustworthy, transparent computing.

Aphaia Pharma to Participate in a Panel Discussion at the 10th LSX World Congress

Retrieved on: 
Tuesday, April 16, 2024
Congress, Obesity, LSX, DSM-IV codes, SAN

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, M.D., Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 10th LSX World Congress , taking place April 29-30, 2024 in London, England.

Key Points: 
  • ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, M.D., Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 10th LSX World Congress , taking place April 29-30, 2024 in London, England.
  • The panel will discuss a unique perspective on the opportunities for biotech companies to treat cardiometabolic disease and obesity.
  • Details on the presentation are as follows:

ORYZON to Provide Corporate Progress Updates at Several Events in April

Retrieved on: 
Friday, April 5, 2024
Conference, Biotechnology, Genomics, LSX, BST, Pharma, Cryptocurrency

Oryzon has been invited to attend the Investing in Oncology Forum 2024, which will be held at the IVA Konferenscenter in Stockholm (Sweden) on April 10, where the company will provide a corporate update at 14:45 CET and will hold one-on-one meetings with global investors and pharmaceutical companies.

Key Points: 
  • Oryzon has been invited to attend the Investing in Oncology Forum 2024, which will be held at the IVA Konferenscenter in Stockholm (Sweden) on April 10, where the company will provide a corporate update at 14:45 CET and will hold one-on-one meetings with global investors and pharmaceutical companies.
  • The company will hold one-on-one meetings with pharmaceutical companies.
  • Oryzon will take part in the keynote plenary panel entitled “The inflation Reduction Act and its Potential Impact On EU Biotech & Pharma Companies: Demystifying the Future” on April 29 at 16:20 BST.
  • Click on the link for more info about the LSX World Congress 2024

Calliditas Therapeutics to Attend Conferences in April

Retrieved on: 
Tuesday, April 9, 2024
Congress, Conference, CALT, Future, Sustainability, LSX, Inflation, Pharma, Person, Pharmaceutical industry

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:

Key Points: 
  • STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:
    Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024.
  • Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings.
  • World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA.
  • Maria Törnsén, President North America, will be moderating a panel, entitled "Partnering in the rare disease space - industry perspective".

Calliditas Therapeutics to Attend Conferences in April

Retrieved on: 
Tuesday, April 9, 2024
Congress, Conference, CALT, Future, Sustainability, LSX, Inflation, Pharma, Person, Pharmaceutical industry

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:

Key Points: 
  • STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:
    Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024.
  • Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings.
  • World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA.
  • Maria Törnsén, President North America, will be moderating a panel, entitled "Partnering in the rare disease space - industry perspective".

VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024

Retrieved on: 
Thursday, March 28, 2024
Health, Surgery, General Health, Research, Science, Pharmaceutical, Biotechnology, Path, LSX, Congress, Business development, Commercialization

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio€quity Europe (12-14 May).

Key Points: 
  • VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio€quity Europe (12-14 May).
  • The LSX World Congress is the leading partnering, strategy and investment event in Europe, with 1:1 partnering at its core.
  • Bio€quity Europe is a key biopartnering event for the biotech industry in Europe, organised by BioCentury.
  • If you are interested in meeting with the VarmX Team at either of these upcoming events, or to get further information, please contact: [email protected] .

Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

Retrieved on: 
Thursday, November 16, 2023
Patient, Culture, ELAS, LSX, Growth, Hypoparathyroidism, Pharmaceutical industry

LYON, France and CAMBRIDGE, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, has been awarded ‘Biotech Company of the Year 2023’ at the annual LSX, European Lifestars Awards Ceremony, held on November 13th in London, U.K.

Key Points: 
  • LYON, France and CAMBRIDGE, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, has been awarded ‘Biotech Company of the Year 2023’ at the annual LSX, European Lifestars Awards Ceremony, held on November 13th in London, U.K.
  • The European Lifestars Awards (ELAs) are an annual event that acknowledges and celebrates the significant achievements within the life sciences sector across Europe.
  • These awards recognize the innovation and ground-breaking achievements of the life sciences industry's most distinguished executive leaders, investors, partners, and dealmakers for their outstanding contributions to the advancement of the industry.
  • Together, we've cultivated a culture of excellence and commitment towards patients, advancing our clinical pipeline of therapeutic peptides for rare endocrine diseases.

Lisata Therapeutics Announces Participation in Upcoming Conferences in November

Retrieved on: 
Thursday, November 9, 2023
LSX, Doctor of Philosophy, Conference, Therapy

Management will also participate in one-on-one meetings with investors that day.

Key Points: 
  • Management will also participate in one-on-one meetings with investors that day.
  • Management will participate in one-on-one meetings at the Jefferies London Healthcare Conference.
  • Dr. Mazzo will deliver a virtual presentation on Wednesday, November 29, 2023 at 6:00pm PT / 9:00pm ET.
  • This is an invitation only event that consists of institutional, industrial, and high net worth investors in the Asia Pacific.

Lazzara Yachts Announces LSX 67 Limited Edition US Premiere, New US Office

Retrieved on: 
Tuesday, October 10, 2023
LSX, Limited Edition, Stainless steel, Carbon, Adventure, LMC, VIP, Water, Interior design, Shipbuilding, Broker

FORT LAUDERDALE, Fla., Oct. 10, 2023 /PRNewswire-PRWeb/ -- "We destroy standards to create new adventures," says David Galante, Lazzara Yachts Executive Vice President, with pride. Breaking standards was required to create the Limited Edition extension of Lazzara Yachts' award-winning LSX 67 model. The LSX 67 Limited Edition has a striking midnight blue exterior and features a long list of fan-favorite upgrades, including a revolutionized master, seamless wood interior, and spacious walkways.

Key Points: 
  • Breaking standards was required to create the Limited Edition extension of Lazzara Yachts' award-winning LSX 67 model.
  • Breaking standards was required to create the Limited Edition extension of Lazzara Yachts' award-winning LSX 67 model.
  • The LSX 67 Limited Edition has a striking midnight blue exterior and features a long list of fan-favorite upgrades, including a revolutionized master, seamless wood interior, and spacious walkways.
  • View the LSX 67 Limited Edition video tour on Lazzara Yachts YouTube channel, click here .